WO2003070154A3 - Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same - Google Patents
Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same Download PDFInfo
- Publication number
- WO2003070154A3 WO2003070154A3 PCT/IN2003/000030 IN0300030W WO03070154A3 WO 2003070154 A3 WO2003070154 A3 WO 2003070154A3 IN 0300030 W IN0300030 W IN 0300030W WO 03070154 A3 WO03070154 A3 WO 03070154A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- formulation
- preparing
- expectorant
- preferred
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Disclosed are pharmaceutical formulations for oral administration through a soft gelatin capsule drug delivery device, wherein the pharmaceutical formulation, in a preferred embodiment, contains Pseudoephedrine HCl and an expectorant as the active ingredients. The active pharmaceutical ingredient is embedded into an oily matrix. The formulation also includes an expectorant; a surfactant; a suspending agent; and a suspension medium, wherein, in a preferred embodiment, the expectorant is guaifenesin, the surfactant is lecithin, the suspending agent is yellow beeswax, and the suspension medium is soybean oil. In a preferred embodiment, the formulation consists essentially of about 30.5 mg by weight of Pseudoephedrine HCI, about 200 mg by weight of guaifenesin, about 0.1- 5.0 mg by weight of yellow beeswax, about 10-15 mg by weight of lecithin; and about 200-300 mg by weight of soybean oil. Also disclosed is a process for preparing the formulation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003230190A AU2003230190A1 (en) | 2002-02-20 | 2003-02-20 | Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN127DE2002 | 2002-02-20 | ||
IN127/DEL/2002 | 2002-02-20 | ||
US10/096,709 | 2002-03-13 | ||
US10/096,709 US20030158265A1 (en) | 2002-02-20 | 2002-03-13 | Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003070154A2 WO2003070154A2 (en) | 2003-08-28 |
WO2003070154A3 true WO2003070154A3 (en) | 2004-05-06 |
Family
ID=27758877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2003/000030 WO2003070154A2 (en) | 2002-02-20 | 2003-02-20 | Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003230190A1 (en) |
WO (1) | WO2003070154A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2412865A (en) * | 2004-04-07 | 2005-10-12 | Atulkumar Sumanbhai Patel | Cough mixture comprising ipecacuanha and guaifenesin |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4716033A (en) * | 1986-03-27 | 1987-12-29 | Warner-Lambert Company | Medicament adsorbates with surfactant and their preparation |
US4797288A (en) * | 1984-10-05 | 1989-01-10 | Warner-Lambert Company | Novel drug delivery system |
US5595758A (en) * | 1993-06-18 | 1997-01-21 | Smithkline Beecham Corporation | Soft-shelled gelatin encapsulated particles |
-
2003
- 2003-02-20 AU AU2003230190A patent/AU2003230190A1/en not_active Abandoned
- 2003-02-20 WO PCT/IN2003/000030 patent/WO2003070154A2/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4797288A (en) * | 1984-10-05 | 1989-01-10 | Warner-Lambert Company | Novel drug delivery system |
US4716033A (en) * | 1986-03-27 | 1987-12-29 | Warner-Lambert Company | Medicament adsorbates with surfactant and their preparation |
US5595758A (en) * | 1993-06-18 | 1997-01-21 | Smithkline Beecham Corporation | Soft-shelled gelatin encapsulated particles |
Also Published As
Publication number | Publication date |
---|---|
AU2003230190A1 (en) | 2003-09-09 |
AU2003230190A8 (en) | 2003-09-09 |
WO2003070154A2 (en) | 2003-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5525920B2 (en) | Orally dispersible tablets containing fexofenadine | |
ES2668381T3 (en) | Disintegration tablets by mouth and manufacturing methods | |
EP1279402B1 (en) | Coated granules of allylamine-or benzylamine-anti-mycotics, process for preparation thereof and orodispersible tablets containing said coated granules | |
EP1059084B1 (en) | Rapidly absorbed liquid compositions containing an amine and a NSAID | |
WO2005046640A3 (en) | Multi-site drug delivery platform | |
US20080286356A1 (en) | Pharmaceutical compositions containing terbinafin and use thereof | |
JP2011057683A (en) | Sustained release formulation comprising lamotrigine | |
JP2005527522A (en) | Sustained release tablets based on microcapsules | |
HUP0201877A2 (en) | Fast-dispersing dosage forms containing fish gelatin | |
RS50937B (en) | Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus | |
US20070264332A1 (en) | Sustained Release Pharmaceutical Formulation | |
CA2451519C (en) | Tablet comprising cetirizine and pseudoephedrine | |
AU2002321249A1 (en) | Pharmaceutical compositions containing terbinafin and use thereof | |
WO2003070155A3 (en) | Orally administrable pharmaceutical formulation | |
JP2005522467A5 (en) | ||
WO2003070154A3 (en) | Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same | |
WO2003070156A3 (en) | Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same | |
WO2003101378A3 (en) | Pharmaceutical formulation in a drug delivery system and process for preparing the same | |
WO2003099214A3 (en) | Biguanide formulations | |
KR20080073342A (en) | Zolpidem tablets | |
CA3178398A1 (en) | Compositions and methods for hardening | |
JP2006501211A (en) | Pharmaceutical composition containing a combination of epinastine, pseudoephedrine and methylephedrine | |
US6926906B2 (en) | Orally administrable pharmaceutical formulation | |
US20080311196A1 (en) | All Day Rhinitic Condition Treatment Regimen | |
US20060122194A1 (en) | Tablet comprising efletirizine and pseudoephedrine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |